Press Releases
Samsung Biologics 2024 | Year in Review
This year, Samsung Biologics continued to work side-by-side with clients, supporting the delivery of high-quality biopharmaceuticals to patients with unmet needs and contributing to a healthier tomorrow. As we bid 2024 farewell, here’s a look back at the key highlights that defined Samsung Biologics during the past 12 months and laid the foundation for another successful year to come.
Building Trusted Partnerships
Leveraging our track record of expertise and continued expansion in capacity and service offerings, Samsung Biologics extended partnerships with clients across the US, Europe, and Asia. Serving over 110 clients, including 17 of the world’s top 20 pharmaceutical companies, 2024 saw a number of significant deals. With utmost priority on quality and client satisfaction, we took the extra mile to tailor services to meet evolving demands with agility.
▶ Samsung Biologics signs manufacturing deal with European pharmaceutical company
▶ Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company
▶ Bringing flexible solutions to champion shared commitment to saving lives
▶ Samsung Biologics recognized for service excellence receiving CDMO Leadership Awards for 11th year
Frontrunner in Sustainability
As a sustainable CDMO partner, Samsung Biologics remains steadfast in its commitment to embed ESG practices across all operations. The company received global recognition for its progress in decarbonization and activities to engage suppliers in building sustainable value chains for net-zero health systems.
▶ Samsung Biologics listed in 2024 Dow Jones Sustainability World Index
▶ Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
▶ Samsung Biologics awarded Leadership status by CDP for climate action efforts
▶ Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
Competitive Edge in Drug Development
On top of capacity expansion to meet growing market demand, Samsung Biologics also makes bold investments in advanced technologies to enhance its capabilities to support complex projects, including multispecific antibodies. In 2024, the company launched a number of tech development platforms to enhance therapeutic efficacy, accelerate timelines, and ensure highest quality.
▶ Samsung Biologics CDO: Geared towards fusion protein medicines
▶ Samsung Biologics launches development platforms for enhanced therapeutic efficacy
▶ Agile. Flexible. Focused on You.
Continuous Pursuit of Excellence
Samsung Biologics continues to build on its core strengths and deliver on its commitment to superior client satisfaction though operational excellence, innovation, and highest quality. The company makes it a priority to cultivate a quality mindset and culture among all employees, while continuing to find improvement points to optimize processes and maximize efficiency.
▶ What defines a quality culture at Samsung Biologics?
▶ Optimized operations for reliable biomanufacturing
▶ Virtual technologies to enhance quality mindset and transform learning culture
▶ The “Samsung Biologics Way” builds trust and ensures client satisfaction
In 2025, Samsung Biologics will open a new phase of growth at Bio Campus II with the completion of Plant 5 as well as the launch of comprehensive ADC services at our dedicated facility. We will look forward to another year of boundless opportunities and collaboration with our clients to support their biologics’ journey, and ultimately help patients.
Want to stay on top of news from Samsung Biologics?
Sign up for our monthly newsletter or visit our Newsroom!
This year, Samsung Biologics continued to work side-by-side with clients, supporting the delivery of high-quality biopharmaceuticals to patients with unmet needs and contributing to a healthier tomorrow. As we bid 2024 farewell, here’s a look back at the key highlights that defined Samsung Biologics during the past 12 months and laid the foundation for another successful year to come.
Building Trusted Partnerships
Leveraging our track record of expertise and continued expansion in capacity and service offerings, Samsung Biologics extended partnerships with clients across the US, Europe, and Asia. Serving over 110 clients, including 17 of the world’s top 20 pharmaceutical companies, 2024 saw a number of significant deals. With utmost priority on quality and client satisfaction, we took the extra mile to tailor services to meet evolving demands with agility.
▶ Samsung Biologics signs manufacturing deal with European pharmaceutical company
▶ Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company
▶ Bringing flexible solutions to champion shared commitment to saving lives
▶ Samsung Biologics recognized for service excellence receiving CDMO Leadership Awards for 11th year
Frontrunner in Sustainability
As a sustainable CDMO partner, Samsung Biologics remains steadfast in its commitment to embed ESG practices across all operations. The company received global recognition for its progress in decarbonization and activities to engage suppliers in building sustainable value chains for net-zero health systems.
▶ Samsung Biologics listed in 2024 Dow Jones Sustainability World Index
▶ Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
▶ Samsung Biologics awarded Leadership status by CDP for climate action efforts
▶ Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
Competitive Edge in Drug Development
On top of capacity expansion to meet growing market demand, Samsung Biologics also makes bold investments in advanced technologies to enhance its capabilities to support complex projects, including multispecific antibodies. In 2024, the company launched a number of tech development platforms to enhance therapeutic efficacy, accelerate timelines, and ensure highest quality.
▶ Samsung Biologics CDO: Geared towards fusion protein medicines
▶ Samsung Biologics launches development platforms for enhanced therapeutic efficacy
▶ Agile. Flexible. Focused on You.
Continuous Pursuit of Excellence
Samsung Biologics continues to build on its core strengths and deliver on its commitment to superior client satisfaction though operational excellence, innovation, and highest quality. The company makes it a priority to cultivate a quality mindset and culture among all employees, while continuing to find improvement points to optimize processes and maximize efficiency.
▶ What defines a quality culture at Samsung Biologics?
▶ Optimized operations for reliable biomanufacturing
▶ Virtual technologies to enhance quality mindset and transform learning culture
▶ The “Samsung Biologics Way” builds trust and ensures client satisfaction
In 2025, Samsung Biologics will open a new phase of growth at Bio Campus II with the completion of Plant 5 as well as the launch of comprehensive ADC services at our dedicated facility. We will look forward to another year of boundless opportunities and collaboration with our clients to support their biologics’ journey, and ultimately help patients.
Want to stay on top of news from Samsung Biologics?
Sign up for our monthly newsletter or visit our Newsroom!